Key Takeaways
- Q2 net income reached $361.8 million, translating to $1.10 per diluted share, a dramatic reversal from the 89-cent loss reported in the prior-year quarter
- Top-line growth accelerated 70% on a year-over-year basis to $4.88 billion, surpassing the Street’s $4.73 billion projection
- The medical loss ratio showed significant improvement at 79.2%, compared to 91.1% in the second quarter of 2025
- Management boosted its full-year earnings from operations outlook to $500 million-$700 million from the previous $250 million-$450 million range
- Shares of OSCR declined approximately 9% on Thursday, erasing an 8.9% premarket rally
Oscar Health delivered what could be considered one of its most impressive quarterly performances to date on Thursday, yet investors responded by sending shares sharply lower.
OSCR shares retreated roughly 9% during Thursday’s session on August 6, completely reversing an almost 9% gain seen in premarket trading. Shares had settled at $30.11 during Wednesday’s close. Even with Thursday’s selloff, the stock remains up an impressive 110% year-to-date in 2026, far outpacing the S&P 500’s 13% advance.
The health insurance provider delivered second-quarter earnings of $1.10 per share, demolishing the Wall Street consensus forecast of 40 cents. Total revenue jumped 70% to reach $4.88 billion, topping the $4.73 billion analysts had penciled in.
Looking at the first six months of 2026, Oscar generated net income of $1.04 billion, equivalent to $3.16 per share. This marks a substantial improvement from the $46.9 million earned during the corresponding period last year.
MLR Performance Steals the Spotlight
The company’s medical loss ratio dropped to 79.2% during the second quarter, representing a significant decline from the 91.1% recorded in Q2 2025. This metric came in better than the Street’s 81.2% expectation, marking an impressive achievement. Management attributed the improvement to strategic pricing discipline and $164 million in favorable prior period reserve adjustments.
Oscar increased its full-year earnings from operations projection to between $500 million and $700 million, representing a substantial upgrade from the previous $250 million to $450 million guidance. The company maintained its total revenue guidance at $18.7 billion to $19 billion.
Total membership reached 2.9 million as of June 30, representing 46% growth compared to the prior year. This expansion is particularly notable given that ACA enrollment nationwide declined by approximately three million members following the expiration of temporary federal subsidies late last year.
Major competitors like CVS Health’s Aetna withdrew from the ACA individual marketplace this year. Cigna announced plans to exit in 2027. Oscar has chosen the contrarian approach.
Member Attrition Concerns Emerge
What explains the stock’s decline despite strong results? Stephens analyst Raj Kumar suggested that concerns about potential membership attrition during the year’s second half likely weighed on sentiment.
Membership numbers had already experienced a modest decline from 3.2 million at the end of March to 2.96 million by June 30. During the earnings conference call, CEO Mark Bertolini acknowledged expectations for “further market contraction.”
Kumar highlighted that potential membership churn “could add additional risk” to the company’s outlook. Unlike larger, more diversified insurance competitors, Oscar’s business model is entirely concentrated in the ACA marketplace.
Baird’s Michael Ha characterized the quarterly performance as “an important proof point for the earnings thesis,” while cautioning that investors holding the stock must maintain confidence that the ACA exchange “remains structurally viable as enrollment and market composition evolve.”
Wall Street analysts maintain an average Hold rating on OSCR, with a consensus price target of $26.09, per FactSet data.
CEO Bertolini expressed confidence that the company is moving into the second half of 2026 “from a position of strength, with the technology, scale, and operating discipline to deliver profitable growth.”
Notably, the analyst consensus price target of $26.09 trades below where shares were valued prior to Thursday’s retreat.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
